Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Meta-analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority.

Witjes H, Khatri A, Diderichsen PM, Mandema J, Othman AA.

Clin Pharmacol Ther. 2019 Sep 10. doi: 10.1002/cpt.1624. [Epub ahead of print]

PMID:
31502263
2.

Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis.

Xu S, Zhang X, Pan M, Shuai Z, Xu S, Pan F.

Int Immunopharmacol. 2019 Oct;75:105841. doi: 10.1016/j.intimp.2019.105841. Epub 2019 Aug 26.

PMID:
31465912
3.

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.

Reich K, Gooderham M, Tha├ži D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C.

Lancet. 2019 Aug 17;394(10198):576-586. doi: 10.1016/S0140-6736(19)30952-3. Epub 2019 Jul 4. Erratum in: Lancet. 2019 Jul 16;:.

PMID:
31280967
4.

State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis.

Gisondi P, Geat D, Pizzolato M, Girolomoni G.

Curr Opin Pharmacol. 2019 Jun;46:90-99. doi: 10.1016/j.coph.2019.05.007. Epub 2019 Jun 15. Review.

PMID:
31212119

Supplemental Content

Loading ...
Support Center